Many clinical trials of new cancer drugs may be inappropriately excluding some people with “Duffy-null phenotype,” a trait found predominantly in people of African or Middle Eastern descent, researchers at Dana-Farber Cancer Institute and Queen Mary University of London report in a new study.
Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence – Pharmaceutical Technology
Biogen’s acquisition of HI-Bio’s anti-CD38 monoclonal antibody will expand its immunology presence. Image credit: Shutterstock / Tada Images. As Eli Lilly’s Kisunla (donanemab) enters the
July 3, 2024